Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NR0B1 | P51843 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9867135 | 1.00 | KDM4E (0.41) | KDM4ENR0B1GAAHTTPAX8 | |
| SCHEMBL31202904 | 0.86 | KDM4E (0.55) | KDM4ENR0B1GAAHTTPAX8 | |
| SCHEMBL4242007 | 0.82 | KDM4E (0.38) | KDM4ENR0B1GAAHTTMEN1 | |
| SCHEMBL4237629 | 0.75 | KMT2A (0.44) | KDM4ENR0B1GAAHTTPAX8 | |
| SCHEMBL4240492 | 0.74 | HPGD (0.50) | GAAHTTMEN1KMT2AALDH1A1 | |
| SCHEMBL13743252 | 0.70 | KMT2A (0.46) | KDM4EMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL4246713 | 0.70 | NR0B1 (0.64) | NR0B1GAACYP3A4CYP2C19 | |
| SCHEMBL4246061 | 0.67 | NR0B1 (0.50) | NR0B1ALDH1A1 | |
| SCHEMBL2867325 | 0.64 | MEN1 (0.41) | GAAHTTPAX8MEN1KMT2A | |
| SCHEMBL10007462 | 0.63 | KDM4E (0.53) | KDM4ENR0B1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203694-A1 | INHIBITORS OF UNDECAPRENYL PYROPHOSPHATE SYNTHASE | HURLEY TIMOTHY BRIAN | 2009-08-13 | — | — | US | disclosed |
| US-5061808-A | 2-oxo-1-pyrrolidine carboxylic acid esters | WARNER-LAMBERT COMPANY (US) | 1991-10-29 | — | — | US | disclosed |
| US-4876343-A | Process for statine and statine analogs | WARNER-LAMBERT COMPANY (US) | 1989-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203694-A1 | INHIBITORS OF UNDECAPRENYL PYROPHOSPHATE SYNTHASE | FDPS, UMPS, GGPS1 | KDM4E 3718/4885NR0B1 2001/4885GAA 632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.